Adial Pharmaceuticals Q2 net income $1.1M; plans two Phase 3 trials for AD04

ADIAL PHARMACEUTICALS, INC.

2023-Q2 EPS reported -$1.66

Net income of $1.1M vs net loss of $3.8M in Q2 2022; includes $2.66M gain from Purnovate sale.
Cash and equivalents $1.2M at June 30, 2023, down from $4.0M at Dec 31, 2022; runway into Q1 2024.
Sale of Purnovate subsidiary reduces cash burn; Adial received $450K upfront, up to $83M in milestones plus 19.9% equity stake in Adovate.
FDA confirmed primary endpoint (Percentage No Heavy Drinking Days) for AD04; planning two parallel Phase 3 trials.
R&D expense down 37%, G&A down 59% YoY due to lower trial activities and cost reductions.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ADIAL PHARMACEUTICALS, INC. reported second quarter of 2023 results: net income $1.1 million.

Period: second quarter of 2023
Net income: $1.1 million
Result: reported results

Exact text from the filing

Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-069142

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.